RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue4,48420,38328,8958,250
Cost of Revenue46,26963,44662,82567,696
Gross Profit-41,785-43,063-33,930-59,446
Operating Expenses
Research Development----
Selling General and Administrative37,83120,90817,81322,501
Non Recurring----
Total Operating Expenses84,10084,35480,63899,499
Operating Income or Loss-79,616-63,971-51,743-91,249
Income from Continuing Operations
Total Other Income/Expenses Net1,624-5,245279341
Earnings Before Interest and Taxes-79,616-63,971-51,743-91,249
Interest Expense----
Income Before Tax-77,992-69,216-51,464-90,908
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-77,992-69,216-51,464-90,908
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-77,992-69,216-51,464-90,908
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-77,992-69,216-51,464-90,908